Recently published research showing that Constant Therapy’s evidence-based cognitive, speech, and language program demonstrated safety and feasibility in a small-scale study of patients with mild cognitive impairment (MCI) secondary to Alzheimer’s disease (AD) was cited in Neurology Live. The article is entitled, Cognitive Training With Constant Therapy Shows Feasibility in Early-Stage Alzheimer Disease. Neurology Live highlighted the research findings that “long-term use of the Constant Therapy program was feasible in a patient population with Alzheimer’s disease, as shown by the rate of adherence (80%) and use of the program over 24 weeks.”
Read the full article here.
